Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback